BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 24333407)

  • 1. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
    Alagiakrishnan K; Sankaralingam S; Ghosh M; Mereu L; Senior P
    Discov Med; 2013 Dec; 16(90):277-86. PubMed ID: 24333407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2.
    Plastino M; Fava A; Pirritano D; Cotronei P; Sacco N; Sperlì T; Spanò A; Gallo D; Mungari P; Consoli D; Bosco D
    J Neurol Sci; 2010 Jan; 288(1-2):112-6. PubMed ID: 19836029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which oral agent to use when metformin is no longer effective?
    Bannon M
    QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
    [No Abstract]   [Full Text] [Related]  

  • 4. What to add in with metformin in type 2 diabetes?
    Petrie JR; Adler A; Vella S
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.
    Levey A; Lah J; Goldstein F; Steenland K; Bliwise D
    Clin Ther; 2006 Jul; 28(7):991-1001. PubMed ID: 16990077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.
    Zhong KL; Chen F; Hong H; Ke X; Lv YG; Tang SS; Zhu YB
    Metab Brain Dis; 2018 Aug; 33(4):1009-1018. PubMed ID: 29626315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis.
    Tian S; Jiang J; Wang J; Zhang Z; Miao Y; Ji X; Bi Y
    Diabetes Metab Res Rev; 2023 Oct; 39(7):e3673. PubMed ID: 37302139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical decisions. Management of type 2 diabetes.
    Goldberg RB; Holman R; Drucker DJ
    N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antidiabetic Drugs and the Kidney].
    Candido R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
    [No Abstract]   [Full Text] [Related]  

  • 12. Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients.
    Domínguez RO; Marschoff ER; González SE; Repetto MG; Serra JA
    Diabetes Res Clin Pract; 2012 Oct; 98(1):68-74. PubMed ID: 22658669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus.
    Hanyu H; Sato T; Kiuchi A; Sakurai H; Iwamoto T
    J Am Geriatr Soc; 2009 Jan; 57(1):177-9. PubMed ID: 19170800
    [No Abstract]   [Full Text] [Related]  

  • 14. [The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].
    Ishmuratova AN; Abramov MA; Kuznetsov KO; Ivanyuta MV; Shakirova ZF; Kitapova AI; Usmonov MD; Chernousova LM; Valeeva LI; Kuznetsova AY; Baislamov AS; Shaihetdinova AR; Mirgaliev AA; Orozberdiev ST; Yakupova KI
    Probl Endokrinol (Mosk); 2023 Nov; 69(5):73-83. PubMed ID: 37968954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 16. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease.
    Sanz C; Andrieu S; Sinclair A; Hanaire H; Vellas B;
    Neurology; 2009 Oct; 73(17):1359-66. PubMed ID: 19858457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance in the brain: an old-age or new-age problem?
    Williamson R; McNeilly A; Sutherland C
    Biochem Pharmacol; 2012 Sep; 84(6):737-45. PubMed ID: 22634336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic Drugs in the Treatment of Alzheimer's Disease.
    Michailidis M; Tata DA; Moraitou D; Kavvadas D; Karachrysafi S; Papamitsou T; Vareltzis P; Papaliagkas V
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
    Cardoso S; Moreira PI
    Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.